Gregory P. Kalemkerian

机构：University of Michigan, Michigan Medicine · ORCID：0000-0003-2404-7420

发表论文 338 篇 · 总被引 11983 次 · h-index 52

代表论文

• Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline (2023 · Journal of Clinical Oncology · 被引 53)
• Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation (2024 · Archives of Pathology & Laboratory Medicine · 被引 37)
• Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC. (2023 · Journal of Clinical Oncology · 被引 20)
• A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer (2023 · Clinical Lung Cancer · 被引 19)
• Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update (2024 · Journal of Clinical Oncology · 被引 15)
• Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2025 · ESMO Open · 被引 12)